血站实验室新型冠状病毒相关检测平台的建立与安全防护

Establishment and Safety Protection of SARS-CoV-2 Related Testing Platform in Pretransfusion Laboratories

目的 建立适合血站实验室的新冠病毒相关检测平台,同时避免生物安全风险发生。方法 通过对自动加样器程序的修改,调整液体曲线,降低注液速度,进行液面下加样及混匀;编辑酶免分析仪方法及LIS程序;修改核酸汇集程序等方法建立自动化的新型冠状病毒相关检测平台。结果 该平台可实现新型冠状病毒肺炎康复者恢复期血浆的IgM与IgG抗体检测、IgG抗体效价自动倍比稀释检测及新冠病毒核酸自动化检测。结论 所建立的新型冠状病毒相关检测平台可实现自动化、标准化的加样与检测,避免生物安全风险,为恢复期血浆的临床治疗提供有利的检测手段。

Objective To establish a SARS-CoV-2 related detection platform suitable for pretransfusion laboratories to avoid biological risks.Methods An automated SARS-CoV-2 detection platform was established by modifying the automatic sampler program,adjusting the liquid curve,reducing the injection speed,performing sub-surface addition and mixing,editing the enzyme immunoassay and LIS program and optimizing the nucleic acid pooling program.Results The IgM and IgG antibody,IgG antibody with its titre,and nucleic acid of coronavirus in plasma from cured COVID-19 patients were successfully detected on the platform.Conclusion The established platform could realize automated and standardized sample addition and detection,and avoid biosafety risks.It may provide a favorable strategy for the recovery period plasma detection which could be helpful in COVID-19 treatment.